Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from ZTS

4 Pharma Stocks to Buy Now for the Long Haul

The pharma industry has experienced tremendous growth in recent years. The industry should continue to grow, driven by the growing market for personalized medicine and e-pharmacies. Hence, pharma stocks Pfizer (PFE), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), and Zoetis (ZTS) might be worth buying for the long term. Also, these companies…

StockNews.com

1 Medical Stock to Get Bullish on Right Now

Medical stock Zoetis (ZTS) has witnessed steady growth despite the market turbulence in the past few months. Moreover, Wall Street analysts expect the stock to soar further. So, considering its robust fundamentals, ZTS might be worth buying now. Keep reading.

StockNews.com

4 Pharma Stocks You Shouldn’t Think Twice About Buying in 2023

Pharma sector usually performs relatively well amid market turmoil due to the inelastic demand for its offerings. Moreover, increased technological advancements should boost the industry’s growth. Hence, pharma stocks Eli Lilly (LLY), AstraZeneca (AZN), Zoetis (ZTS), and Teva Pharmaceutical (TEVA) might be worth buying in 2023. Read more.

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Pharmaceutical Stocks to Invest in This Month

The pharmaceutical industry is rapidly evolving to meet today’s health challenges. The pharmaceutical industry's long-term prospects look bright with a globally aging population set to increase healthcare expenditure. Moreover, given the industry’s ability to stay resilient amid economic headwinds, it could be wise to invest in fundamentally strong pharmaceutical stocks…

StockNews.com

4 Health Care Stocks That Could Keep Your Portfolio From Needing a Check-Up

The healthcare industry tends to withstand macroeconomic pressure better than other industries due to the almost inelastic demand for medical products and services. With a recession expected next year, investors could look to capitalize on the defensive characteristics and long-term prospects of the industry by investing in quality medical stocks…

StockNews.com

2 Stocks That Have Been Boosting Their Dividends Lately

Market volatility is widespread due to increasing odds of a recession amid the persistently high inflation and consecutive interest rate hikes by the Fed. Traders are betting on another aggressive hike this month as the Fed stays determined to bring inflation under control. Thus, we think investors should invest in…

StockNews.com

3 Best Recession-Proof Stocks to Invest in Right Now

As the possibility of the Fed maintaining its hawkish stance to tame the elevated inflation is raising concerns over a potential recession, it could be wise to invest in defensive stocks Dollar Tree (DLTR), UnitedHealth Group (UNH), and Zoetis (ZTS) to make your portfolio recession-proof. Keep reading….

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Here's How Much You Would Have Made Owning Zoetis Stock In The Last 5 Years

Zoetis (NYSE:ZTS) has outperformed the market over the past 5 years by 13.08% on an annualized basis producing an average annual return of 22.15%. Currently, Zoetis has a market capitalization of $79.88 billion.

Benzinga

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,500 Today

Zoetis (NYSE:ZTS) has outperformed the market over the past 5 years by 11.89% on an annualized basis producing an average annual return of 20.56%. Currently, Zoetis has a market capitalization of $75.58 billion.

Benzinga

Here's How Much You Would Have Made Owning Zoetis Stock In The Last 5 Years

Zoetis (NYSE:ZTS) has outperformed the market over the past 5 years by 10.79% on an annualized basis producing an average annual return of 21.83%. Currently, Zoetis has a market capitalization of $79.47 billion.

Benzinga

Zoetis vs. IDEXX Laboratories: Which Animal-Health Services Stock is a Better Buy?

Rising pet ownership and an increasing focus on healthy livestock have boosted the demand for animal healthcare solutions. Therefore, animal healthcare service providers Zoetis (ZTS) and IDEXX Laboratories (IDXX) should benefit. But the stocks of which of these two companies is a better buy now? Read on to learn our…

StockNews.com

Buy These 3 Battered Stocks Before They Rebound

Worries over the Federal Reserve’s aggressive monetary policy tightening have driven an intense sell-off in the stock market of late. As a result, many quality stocks have fallen into oversold territory. Given this backdrop, we think it could be wise to scoop up the beaten-down stocks of fundamentally sound companies…

StockNews.com

3 Pet Stocks to Buy and Hold in 2022

Despite rising pet care costs amid the Russia-Ukraine war and record-high inflation, the demand for pet care products remains strong. And because a significant increase in pet ownership amid the COVID-19 pandemic is expected to keep the demand high, we think it could be wise to scoop up shares of…

StockNews.com

Add These 4 No-Brainer Stocks Down More than 20% to Your Portfolio

Due to the increasing sanctions on Russia, inflationary pressures, and supply chain disruptions, the stock market has been exhibiting high volatility. However, quality stocks Zoetis (ZTS), Accenture (ACN), Micron Technology (MU), and QUALCOMM (QCOM), which declined more than 20% year-to-date, have the potential to rebound quickly. So, these stocks could…

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

3 Beaten-Down Growth Stocks With More Than 50% Upside Potential

The key to taking advantage of the bear market in growth stocks is to look for companies whose earnings momentum and growth are unaffected by changes in economic or monetary conditions. Therefore, investors should consider buying the following 3 high-quality growth stocks: Veeva Systems (VEEV), Resmed, Inc. (RMD), and Zoetis…

Benzinga

Zoetis's Return On Capital Employed Insights

Pulled from Benzinga Pro data, Zoetis (NYSE:ZTS) posted Q4 earnings of $413.00 million, an increase from Q3 of 25.18%. Sales dropped to $1.97 billion, a 1.16% decrease between quarters.

StockNews.com

2 Beaten-Down Pet Stocks Worth Buying Right Now

Pet ownership has skyrocketed during the COVID-19 pandemic, driving the demand for medications, pet food, and other pet-related services. So, beaten-down pet stocks Zoetis (ZTS) and IDEXX Laboratories (IDXX) could bounce back in the near term because the demand for pet-related products and services is expected to grow. So, let’s…

Benzinga

Zoetis Q4 Sales Cushioned By Higher Companion Animal Product Sales, Issues FY22 Outlook

Zoetis Inc (NYSE: ZTS) has reported Q4 FY21 revenue of $2 b

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

4 Top Dividend Growth Stocks to Add to Your Watchlist

Dividend investing is an effective way of generating income with limited concern about market volatility. So, investors looking to assure a consistent flow of income, along with capital appreciation, could consider adding quality dividend stocks Microsoft (MSFT), Eli Lilly (LLY), Zoetis (ZTS), and The TJX (TJX) to their watchlists. These…

StockNews.com

Better Buy for 2022: Zoetis vs. Zomedica

Rising pet ownership and increasing focus on animal health have boosted the demand for animal healthcare solutions. Therefore, Zoetis (ZTS) and Zomedica (ZOM) should benefit. But which of these two stocks is a better buy now? Read more to find out.

StockNews.com

4 Growth Stocks to Buy on the Dip

Amid the current, inflationary environment, the Fed’s recent signal that it will raise interest rates aggressively precipitated a huge market sell-off last week. However, fundamentally sound growth stocks Anthem (ANTM), Zoetis (ZTS), Moderna (MRNA), and Forrester Research (FORR), which witnessed moderate corrections, could rebound soon. So, we think it could…

1 2 3

People

Kritika SarmahHer

727 stories

Dipanjan BanchurSince

722 stories

Santanu RoyHaving

215 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Medical Pharmaceuticals

125 stories

ACN

110 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.